Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 2;8(2):e962.
doi: 10.1212/NXI.0000000000000962. Print 2021 Mar 4.

Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome

Affiliations

Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome

Jana Werner et al. Neurol Neuroimmunol Neuroinflamm. .

Abstract

Objective: To expand the spectrum of anti-IgLON5 disease by adding 5 novel anti-IgLON5-seropositive cases with bulbar motor neuron disease-like phenotype.

Methods: We characterized the clinical course, brain MRI and laboratory findings, and therapy response in these 5 patients.

Results: Patients were severely affected by bulbar impairment and its respiratory consequences. Sleep-related breathing disorders and parasomnias were common. All patients showed clinical or electrophysiologic signs of motor neuron disease without fulfilling the diagnostic criteria for amyotrophic lateral sclerosis. One patient regained autonomy in swallowing and eating, possibly related to immunotherapy.

Conclusion: IgLON5 disease is an important differential diagnosis to evaluate in patients with bulbar motor neuron disease-like phenotype and sleep disorders. There is need for a deeper understanding of the underlying pathobiology to determine whether IgLON5 disease is an immunotherapy-responsive condition.

PubMed Disclaimer

References

    1. Sabater L, Gaig C, Gelpi E, et al. . A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13:575–586. - PMC - PubMed
    1. Gaig C, Graus F, Compta Y, et al. . Clinical manifestations of the anti-IgLON5 disease. Neurology 2017;88:1736–1743. - PMC - PubMed
    1. Nissen MS, Blaabjerg M. Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature. Front Neurol 2019;10:1056. - PMC - PubMed
    1. Gelpi E, Höftberger R, Graus F, et al. . Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016;132:531–543. - PMC - PubMed
    1. Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 2016;13:226. - PMC - PubMed

Publication types

Substances

LinkOut - more resources